Latest stories on QNTM
Quantum BioPharma reports Q4 results
Seeking Alpha56 · neutralearnings
Quantum BioPharma Highlights Year of Financing Moves, Debt Settlement and Governance Changes
TipRanks55 · neutralgeneral
Quantum BioPharma (NASDAQ: QNTM) Announces that Rodman & Renshaw Initiates Coverage with Buy Rating, $8 Price Target
Business Insider61 · neutralanalyst
Rodman & Renshaw Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$8 Price Target
GlobeNewswire61 · neutralanalyst
Quantum BioPharma (NASDAQ: QNTM) to Present at 3rd Annual ArcStone-Kingswood Growth Summit
Business Insider56 · neutralgeneral
Quantum BioPharma Showcases FDA-Backed Lucid-MS Program at Toronto Growth Summit
TipRanks63 · neutralproduct/pr
Quantum BioPharma to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto
GlobeNewswire55 · neutralgeneral
Quantum BioPharma to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto
Business Insider55 · neutralgeneral
Quantum BioPharma Ltd. (NASDAQ: QNTM) Filling Key Gap in MS Treatment, Cleared by FDA to Launch Historic Trials
Business Insider73 · bullishproduct/pr
Quantum BioPharma Ltd. (NASDAQ: QNTM) Filling Key Gap in MS Treatment, Cleared by FDA to Launch Historic Trials
GlobeNewswire73 · bullishproduct/pr
Quantum BioPharma Ltd. NASDAQ: QNTM) Receives FDA Clearance to Begin Trials for Historic MS Treatment
Business Insider73 · bullishproduct/pr
Quantum BioPharma Ltd. NASDAQ: QNTM) Receives FDA Clearance to Begin Trials for Historic MS Treatment
GlobeNewswire73 · bullishproduct/pr
Quantum BioPharma Announces Plans to Voluntarily Delist its Class B Shares from the Canadian Securities Exchange
Business Insider42 · neutralgeneral
Quantum BioPharma Announces Plans to Voluntarily Delist its Class B Shares from the Canadian Securities Exchange
GlobeNewswire48 · neutralgeneral
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Draws ‘Buy’ Rating on Lucid-MS Potential
Business Insider61 · neutralanalyst
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Myelin-Protecting MS Therapy as Treatment Paradigm Evolves
Business Insider63 · neutralproduct/pr
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Reports Lower Q2 Expenses, Advances Lucid-MS Into Phase 2
Business Insider59 · neutralproduct/pr
Quantum BioPharma GAAP EPS of -$0.47
Seeking Alpha28 · bearishearnings
Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial
Business Insider68 · bullishproduct/pr
Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial
GlobeNewswire68 · bullishproduct/pr
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Targets Disability Drivers Beyond Relapse Rates in Multiple Sclerosis
Business Insider56 · neutralproduct/pr
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Receives FDA Clearance to Advance Lucid-MS into Phase 2
Business Insider67 · bullishproduct/pr
Why Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Is ‘One to Watch’
Barchart56 · neutralgeneral
Quantum BioPharma Ltd. (NASDAQ: QNTM) Advancing Innovative, First-in-Class, Patented MS Therapy | QNTM Stock News
StockTitan67 · bullishproduct/pr